drugset / Trial / NCT07416682
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm study to evaluate the safety and efficacy of CAR BCMA-CD70 CAR-T cell therapy for high-risk plasma cell neoplasms.
Timeline
- Start
- 2026-04-14
- Primary completion
- 2027-01-30
- Completion
- 2028-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR BCMA-CD70 T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CAR BCMA-CD70 T cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | CAR BCMA-CD70 T cells | Cell therapy | 3e+06 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |